PHARMACY

Medication adherence could be blockbuster for specialty

BY Alaric DeArment

@font-face {
font-family: “Times New Roman”;
}p.MsoNormal, li.MsoNormal, div.MsoNormal { margin: 0in 0in 0.0001pt; font-size: 12pt; font-family: “Times New Roman”; }table.MsoNormalTable { font-size: 10pt; font-family: “Times New Roman”; }div.Section1 { page: SecWHAT IT MEANS AND WHY IT’S IMPORTANT — At Drug Store News’ Specialty Pharmacy Roundtable event last Tuesday, Diplomat Specialty Pharmacy president and CEO Phil Hagerman remarked that improving medication adherence in specialty pharmacy could be equivalent to a new blockbuster drug. And he may be right.

(THE NEWS: BioPlus Specialty Pharmacy: Services help boost adherence among patients. For the full story, click here)

Poor medication adherence costs the healthcare system nearly $300 billion every year, with more than $100 billion of that resulting from hospitalizations, according to a study in The New England Journal of Medicine. Every prescription that goes unfilled and every dose that goes untaken costs money for individuals, payers, drug makers, retailers and other stakeholders.

The statistics that BioPlus Specialty Pharmacy recently released illustrated the huge difference that comprehensive pharmacy services can make in improving adherence. When pharmacists can work with physicians and identify patients’ adherence problems early on, they can address those problems and, in BioPlus’ case, achieve nearly universal adherence before adherence problems begin to take their unnecessary toll.

Specialty pharmacies are well positioned to take advantage of the close pharmacist-patient relationships they create. For payers, improved adherence means lower spending; for drug makers, it means higher profits; and for patients, it means better outcomes.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Spherix’s diabetes drug may lower HbA1c levels among patients with higher BMIs

BY Alaric DeArment

BETHESDA, Md. — Good results from an investigational diabetes drug made by Spherix may result from higher body mass indexes among U.S. patients, according to results of a late-stage clinical trial announced Thursday.

Spherix said results of the phase-3 trial conducted among American and Indian patients indicated that D-tagatose may be more effective in lowering HbA1c levels due to Americans having higher BMIs on average than Indians.

“Tagatose appears to be more effective in Type 2 diabetes patients with adipocyte dysfunction that no longer permits the adipocytes to act appropriately as an endocrine organ controlling HbA1c,” Spherix president Robert Lodder said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Forbes: Stewart Rahr’s newest pursuit is convincing Trump to challenge Obama in 2012

BY Jim Frederick

WHITESTONE, N.Y. — Fresh from securing a deal to sell his company to Cardinal Health for $1.3 billion, Kinray owner, president and CEO Stewart Rahr is turning more attention to his crusade to promote his friend Donald Trump as a candidate for president in 2012.

So reported Forbes magazine in its online edition. Forbes, which ranked Rahr as the 170th most wealthy American, reported that the colorful and well-connected billionaire is working hard to convince "The Donald" to run for the nation’s highest office.

Rahr agreed in November to sell Kinray, the nation’s top independently owned drug wholesaler, to Cardinal. The deal, expected to close early next year, presumably will leave Kinray’s former owner more time to devote himself to philanthropy — among other charitable pursuits, he is the largest donor behind the Make-A-Wish Foundation — and to back Trump as a Republican presidential candidate.

Among other actions, Rahr has lent his support to a newly launched website, ShouldTrumpRun.com, and issued a statement that seeks to solicit input and potential support for a presidential run by his friend. In that solicitation, he calls Trump “a natural born leader with outstanding ability to inspire others and to accomplish impossible tasks.” He also cited an independent poll from News Max to assert that Trump could win in a head-to-head contest versus President Barack Obama in 2012.

“This is only a starting point to evaluate in the immediate future the possibility that Mr. Trump would entertain running for the office of president of the United States,” Rahr told supporters. “Please join me in trying to convince Donald to consider running for this high office.”

In an interview with ABC News correspondent George Stephanopoulos, Trump described himself as a Republican, and said that if he decided to run, it would be as a Republican. He added, “I’m going to make a decision probably by June [of 2011].” Among the issues he’d champion: a more assertive stance with China, which he declared is gaining the upper hand against the United States in such areas as manufacturing and job creation. “I’m passionate about the country,” Trump told Stephanopoulos.

keyboard_arrow_downCOMMENTS

Leave a Reply

A.FEIN says:
Dec-08-2010 10:38 am

Jim, FYI, I posted Rahr's full email of support for Trump on Drug Channels: http://www.drugchannels.net/2010/12/if-donald-trump-becomes-us-president.html Adam

TRENDING STORIES